Your browser doesn't support javascript.
loading
Evolution of core archetypal phenotypes in progressive high grade serous ovarian cancer.
Nath, Aritro; Cosgrove, Patrick A; Mirsafian, Hoda; Christie, Elizabeth L; Pflieger, Lance; Copeland, Benjamin; Majumdar, Sumana; Cristea, Mihaela C; Han, Ernest S; Lee, Stephen J; Wang, Edward W; Fereday, Sian; Traficante, Nadia; Salgia, Ravi; Werner, Theresa; Cohen, Adam L; Moos, Philip; Chang, Jeffrey T; Bowtell, David D L; Bild, Andrea H.
Afiliación
  • Nath A; Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
  • Cosgrove PA; Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
  • Mirsafian H; Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
  • Christie EL; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Pflieger L; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Copeland B; Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
  • Majumdar S; Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
  • Cristea MC; Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
  • Han ES; Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
  • Lee SJ; Division of Gynecologic Oncology, Department of Surgery, City of Hope, Duarte, CA, USA.
  • Wang EW; Division of Gynecologic Oncology, Department of Surgery, City of Hope, Duarte, CA, USA.
  • Fereday S; Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
  • Traficante N; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Salgia R; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Werner T; Peter MacCallum Cancer Centre, Melbourne, VIC, Australia.
  • Cohen AL; Sir Peter MacCallum Department of Oncology, The University of Melbourne, Melbourne, VIC, Australia.
  • Moos P; Department of Medical Oncology and Therapeutics, City of Hope Comprehensive Cancer Center, Monrovia, CA, USA.
  • Chang JT; Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Bowtell DDL; Division of Oncology, Department of Medicine, Huntsman Cancer Institute, University of Utah, Salt Lake City, UT, USA.
  • Bild AH; Department of Pharmacology and Toxicology, University of Utah, Salt Lake City, UT, USA.
Nat Commun ; 12(1): 3039, 2021 05 24.
Article en En | MEDLINE | ID: mdl-34031395
The evolution of resistance in high-grade serous ovarian cancer (HGSOC) cells following chemotherapy is only partially understood. To understand the selection of factors driving heterogeneity before and through adaptation to treatment, we profile single-cell RNA-sequencing (scRNA-seq) transcriptomes of HGSOC tumors collected longitudinally during therapy. We analyze scRNA-seq data from two independent patient cohorts to reveal that HGSOC is driven by three archetypal phenotypes, defined as oncogenic states that describe the majority of the transcriptome variation. Using a multi-task learning approach to identify the biological tasks of each archetype, we identify metabolism and proliferation, cellular defense response, and DNA repair signaling as consistent cell states found across patients. Our analysis demonstrates a shift in favor of the metabolism and proliferation archetype versus cellular defense response archetype in cancer cells that received multiple lines of treatment. While archetypes are not consistently associated with specific whole-genome driver mutations, they are closely associated with subclonal populations at the single-cell level, indicating that subclones within a tumor often specialize in unique biological tasks. Our study reveals the core archetypes found in progressive HGSOC and shows consistent enrichment of subclones with the metabolism and proliferation archetype as resistance is acquired to multiple lines of therapy.
Asunto(s)

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Fenotipo / Cistadenocarcinoma Seroso Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Neoplasias Ováricas / Fenotipo / Cistadenocarcinoma Seroso Tipo de estudio: Prognostic_studies Límite: Female / Humans Idioma: En Revista: Nat Commun Asunto de la revista: BIOLOGIA / CIENCIA Año: 2021 Tipo del documento: Article País de afiliación: Estados Unidos
...